TrialAnnals of the rheumatic diseases2016

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.

Tsutomu Takeuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.